Overview

Phase I, Pharmacokinetic, Pharmacodynamic Trial of PTK787 and Paclitaxel in Combination for Advanced Solid Tumors

Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
This study will evaluate PTK787, a new oral drug that stops blood vessel development, in combination with Paclitaxel in patients with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Indiana University School of Medicine
Collaborator:
Novartis
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel
Vatalanib